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Randomized trial comparing endovenous laser
ablation of the great saphenous vein with high
ligation and stripping in patients with varicose
veins: Short-term results
Lars H. Rasmussen, MD, DMSC, Lars Bjoern, MD, Martin Lawaetz, BS, Allan Blemings, MSc,
Birgit Lawaetz, RN, and Bo Eklof, MD, PhD, Naestved and Roskilde, Denmark
Background: Endovenous laser (EVL) ablation of the great saphenous vein (GSV) is thought to minimize postoperative
morbidity and reduce work loss compared with high ligation and stripping (HL/S). However, the procedures have not
previously been compared in a randomized trial with parallel groups where both treatments were performed in tumescent
anesthesia on an out-patient basis.
Methods: Patients with varicose veins due to GSV insufficiency were randomized to either EVL (980 nm) or HL/S in
tumescent anesthesia.Miniphlebectomies were also performed. Patients were examined preoperatively and at 12 days, and
1, 3, and 6 months postoperatively. Sick leave, time to normal physical activity, pain score, use of analgesics, Aberdeen
score, Medical Outcomes Study Short Form-36 quality-of-life score, Venous Clinical Severity Score (VCSS), and
complication rates were investigated. The total cost of the procedures, including lost wages and equipment, was
calculated. Cost calculations were based on the standard fee for HL/S with the addition of laser equipment and the
standard salary and productivity level in Denmark.
Results: A follow-up of 6 months was achieved in 121 patients (137 legs). The groups were well matched for patient and
GSV characteristics. Two HL/S procedures failed, and three GSVs recanalized in the EVL group. The groups
experienced similar improvement in quality-of-life scores and VCSS score at 3 months. Only one patient in the HL/S
group had a major complication, a wound infection that was treated successfully with antibiotics. The HL/S and EVL
groups did not differ in mean time to resume normal physical activity (7.7 vs 6.9 calendar days) and work (7.6 vs 7.0
calendar days). Postoperative pain and bruising was higher in the HL/S group, but no difference in the use of analgesics
was recorded. The total cost of the procedures, including lost wages, was €3084 ($3948 US) in the HL/S and €3396
($4347 US) in the EVL group.
Conclusions: This study suggests that the short-term efficacy and safety of EVL and HL/S are similar. Except for slightly
increased postoperative pain and bruising in the HL/S group, no differences were found between the two treatment
modalities. The treatments were equally safe and efficient in eliminating GSV reflux, alleviating symptoms and signs of
GSV varicosities, and improving quality of life. Long-term outcomes, particularly with respect to recurrence rates, shall
be investigated in future studies, including the continuation of the present. ( J Vasc Surg 2007;46:308-15.)Varicose veins are a common problem that affect ap-
proximately 25% of Western adults.1 The condition is most
often caused by great saphenous vein (GSV) insufficiency.
Although varicose veins in early phases are benign and may
be asymptomatic, common associated problems include
pain, itching, night cramps, fatigue, heaviness, and in a
proportion of patients, chronic venous insufficiency char-
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308acterized by ankle edema, eczema, hyper pigmentation,
and leg ulceration.2,3
Until recently, the standard surgical treatment of GSV
insufficiency has been high ligation and stripping (HL/S)
to knee level combined with phlebectomies.4 Such treat-
ment has been shown to reduce the rate of reoperation
compared with high ligation and phlebectomies only.5 In
addition,HL/S has been shown to improve disease-specific
and general quality of life of the patients.6,7 However, the
operation may be associated with significant postoperative
pain and bruising, prolonged sick leave, and occasionally,
complications such as bleeding, groin infection, phlebitis,
and nerve damage8,9 may occur. The procedure is often
performed with general or regional anesthesia, which in-
creases costs, although it may also be performed with
tumescent anesthesia with good patient comfort.10
In the past decade, minimally invasive techniques to
abolish GSV reflux have been developed, including en-
dovenous thermal ablation of the GSV with laser energy
(EVL).11,12 When performed as an office-based procedure
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tively eliminate the GSV from the circulation.13,14 In addi-
tion, closure rates of the GSV 90% for up to 3 years have
been achieved.
Compared with historic controls, EVL has been re-
ported to be associated with a lower complication rate,
higher patient preference, reduced postoperative pain,
shorter sick leave, and a faster resumption of the normal
activities, than HL/S.13-15 Such advantages may compen-
sate the extra costs of the laser equipment, which include a
generator and disposable introducer catheters and fibers.
So far, no randomized controlled trials (RCT) have been
published comparing EVL with HL/S with respect to the
variables safety and efficacy, postoperative morbidity, sick
leave, as well as quality of life and costs. Such trials are
important, however, before the new treatment can be rec-
ommended as a standard treatment of varicose veins.
This article describes the short-term results for these
variables in a randomized trial comparing EVL and HL/S
in patients with varicose veins due to GSV insufficiency.
The study was approved by the Regional Ethics Commit-
tee. The EVL equipment was, in part, provided by Biolitec
AG (Bonn, Germany) and Micronmed (Kristianstad, Swe-
den).
PATIENTS AND METHODS
The study was designed as a consecutive randomized
trial at two participating centers. Every treatment proce-
dure was performed by one of two experienced surgeons
who both had performed 100 EVL procedures and
1000 HL/S procedures before start of the study. The
patients were all referred for varicose vein treatment by
their family physician and were randomized in blocks of 10
sealed envelopes to either HL/S or EVL. In addition to the
main treatment, miniphlebectomies were performed with
the intention of removing all varicosities during the same
procedure.
Inclusion criteria were varicose veins, CEAP C2-4Ep-
AsPr, informed consent, age 18 to 80 years, and GSV
incompetence as defined by reflux time 0.5 seconds by
duplex imaging (Hawk 7-10 MHz probe, BK Medical,
Herlev, Denmark).16 The patients were examined in the
standing position, and the reflux was measured after man-
ual compression of the calf. Bilateral treatment was permit-
ted, provided both limbs received the same treatment dur-
ing the same operation. Previous high ligation with a
preserved and refluxing GSV to the groin was also permit-
ted.
Exclusion criteria were duplication of the saphenous
trunk or an incompetent anterior accessory GSV, small
saphenous vein reflux until 3 months after removal of such
vein, previous deep venous thrombosis, history of arterial
insufficiency or ankle-brachial index 0.9, or both, axial
deep venous insufficiency (femoral or popliteal vein, or
both) and tortuous GSV rendering the vein unsuitable for
the treatment.
Treatment. All the treatments were performed as an
office-based procedure. The surgical team was the same inthe two groups, and consisted of the surgeon assisted by a
nurse. Treatment of the GSV was performed from just
below the knee or from the most distal point of GSV reflux
in the thigh to the saphenofemoral junction. All treatments
were performed with tumescent anesthesia administered
with a syringe under ultrasound guidance to ensure a
homogenous layer of tumescent fluid around the GSV
(lidocaine, 4 mg; adrenaline, 4 g; dinatriumedta, 0.5 mg;
and saline, 8.2 mg in 1 mL of sterile water; with 1 mL
natrium bicarbonate, 84 g/L per 10 mL solution, added
immediately before use) using approximately 250 mL per
treatment. A light sedative (midazolam and alfentanil or
diazepam) was administered intravenously before the pro-
cedure in most cases.
The EVL procedure was performed under duplex guid-
ance with a 980-nm diode laser (Ceralas D 980, Biolitec),
using pulse mode with 1.5-second impulse, 1.5-second
pause, and 12 W of energy. The GSV was accessed percu-
taneously or, in two cases, by means of a small cutdown at
the distal point of access. The catheter was advanced until it
was 1 to 2 cm below the saphenofemoral junction.17
High ligation and perforate invagination stripping was
performed through a groin incision of 4 to 6 cm, with flush
division of the GSV and division of all tributaries behind the
second level of the division.18 If the vein broke during
HL/S, attempts were made to remove it through a separate
access below the knee. In both groups, all varicosities were
removed through miniphlebectomies, which were left
open.
After the procedure, the leg was wrapped in sterile
absorbent bandages and covered with a compressive cohe-
sive bandage (Co-plus, Smith & Nephew, London, UK).
After 48 hours, the patients removed the bandage and were
told to wear a class 1 compressive stocking during the day
for at least 2 weeks.
All treatment procedures were scheduled to last about
75 minutes, including preparations. After the treatment,
the patients were observed for half an hour in the clinics and
discharged with a prescription of diclofenac (50 mg) as the
only prescribed medication. The patients were told to use
the medication when necessary. At the initial visit and
immediately after the treatment, the patients were encour-
aged verbally and in writing to go to work as soon as they
felt able to.
Assessments. The patients were seen and examined at
the time of randomization and attended follow-up at 12
days and at 1, 3, and 6months postoperatively. Assessments
will continue at yearly intervals for a total of 5 years. At the
initial visit, the medical history was obtained, a clinical and
duplex examination was performed, and the CEAP stage
was determined.
The Varicose Vein Severity Score (VVSS), the Aber-
deen Varicose Vein Symptoms Severity Score (AVVSS),
and the Medical Outcomes Study Short Form 36 (SF-36)
health-related quality-of-life score were recorded.19 The
AVVSS is a validated instrument to measure disease-specific
quality of life in patients with varicose veins. It produces a
score from 0 (no venous symptoms) to 100 (worst venous
s (rang
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life instrument which consists of eight domains: physical
functioning (PF), role-physical (RP), bodily pain (BP),
general health (GH), vitality (VT), social functioning (SF),
role-emotional (RE) and mental health (MH). Each do-
main is scored from 0 (worst score) to 100 (best score).21
The duration of reflux and the diameter of the GSV 3
cm below the saphenofemoral junction were measured. At
all follow-up visits, the patients were examined clinically
and with a duplex scan by the surgeon. The patients were
asked to indicate the exact date of returning to work and
normal activity. The technical result and complications
were recorded, and the patients completed the AVVSS and
the SF-36. The research nurse recorded the pain score,
AVVSS, and the SF-36 score, and the calculations of scores
were performed by the statistician.
Criteria for technical success were closed GSV with lack
of flow in the EVL group and absent GSV in the HL/S
group. Recanalized GSV or treatment failure was defined as
an open part of the treated vein segment 5 cm in length.
Complications were regarded as minor if they required no
therapy and major if they required therapy, hospitalization,
led to permanent adverse sequelae, or death.
During the first 10 postoperative days at the end of the
day, the patients were asked to indicate pain score on a
Visual Analogue Scale from 0 to 10 and to record the intake
of analgesics.22 Calculations of costs were based on the
standard fee for HL/S with the addition of the costs of
EVL equipment and the standard salary and productivity
level in Denmark. The impact of sick leave on costs was
corrected for weekends.
Statistical methods. Data were analyzed according to
intention to treat. The primary end point for the entire
study was closed or absent GSV, and secondary end points
were pain, absence from work and normal activity, and
scores for SF-36, AVVSS, and VVSS. A priori sample size
Table I. Patient characteristics, CEAP classification of trea
Characteristics* HL
Patients (n) 59
Legs (n) 68
Age, mean years 54 (22
Sex (n)
Female 43
Male 16
CEAP, n (%)
C2 51 (86
C3 5 (8)
C4 3 (5)
Great saphenous vein
Diameter (mm) 7.6  2.1
Reflux time (s) 2.5  1.0
Treated length (cm)
Total energy (J)
Laser energy (J/cm)
HL/S, High ligation and stripping; EVL, endovenous laser.
*Categoric data are presented as n and n (%); and continuous data as meancalculations indicated that to detect a 15% difference inclosed or absent vein between the groups with   5 and 
 80, 60 legs would be needed in each group. With respect
to pain score and the BP domain in SF-36, 46 patients in
each group would be necessary to describe a significant
difference of 20%.
Efficacy and safety were assessed for the full analysis set,
comprising all patients undergoing either EVL ablation or
HL/S. Descriptive summary statistics were used for safety
analysis. Efficacy end points, AVVSS, SF-36 score, and pain
score were analyzed using analysis of variance with repeated
measures. The time from treatment to resuming work or
normal activity was analyzed using log-rank statistics. For
the Venous Clinical Severity Score (VCSS) and the number
of days on pain medication, intergroup comparisons were
made by Mann-Whitney statistics and intragroup compar-
isons by Friedman statistics. Level of significance was set at
5% level.
RESULTS
The study screened 1135 consecutive patients referred
for varicose vein treatment or investigation by their family
doctor. Between August 2005 and July 2006, 121 patients
(137 legs) were eligible and willing to participate and were
randomized to receive treatment. The groups were well
matched for the demographic data, CEAP classification,
and GSV details as summarized in Table I,which also shows
the EVL energy deposition. Eight patients in each group
had previous high ligation. Most patients were C2 in both
groups.
The number of patients at risk and the technical results
are listed in Table II. Two GSVs were not stripped success-
fully in the HL/S group because the veins broke during the
procedure, and in the EVL group, two GSVs recanalized at
3 months and one at 6 months.
Adverse events were few and are also listed in Table II.
Only one event in a patient with infection in the groin after
legs, great saphenous vein details, and laser energy
EVL
62
69
53 (26-79)
41
21
50 (81)
3 (5)
9 (15)
3) 7.9  2.7 (3-16.5)
) 2.6  1.1 (1-5)
32.9  6.9 (12-50)
2416.7  594.9 (962-3878)
73.5  7.9 (57-95.4)
e) and means  standard deviation (range).ted
/S
-78)
)
(4-1
(1-5HL/S was classified as a major complication. This patient
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tal. One patient in the EVL group presented with extension
of the saphenous thrombus into the femoral vein. The
thrombus dissolved spontaneously without anticoagula-
tion. All other adverse events were minor and self-limiting.
Bruising at 12 days was the most common, but was rela-
tively infrequent: 15 patients in the HL/S group and seven
patients in the EVL group had bruising at 12 days (P 
.05).
Pain score was slightly higher initially after HL/S com-
pared with EVL, and after 10 days, some patients still
experienced pain (Fig 1, P  .01). However, the respective
mean times to resume normal activity (7.7 vs 6.9 calendar
days) and work (7.6 vs 7.0 calendar days) did not differ
significantly between the HL/S and EVL groups (Table
III). No difference in the mean use of analgesics was
recorded: EVL group, 12.9 tablets; and HL/S group, 12
Table II. Number of patients followed up, surgical outco
Results 12 days
HL/S
Lost to follow-up or not seen (n) 0
GSVs for HL/S/stripped (n) 68/66
Complications, n (%)
Infection 1 (2)
Phlebitis 2 (3)
Bruising 15 (25)
Hematoma 5 (8)
Paresthesias —
EVL
Lost to follow-up or not seen (n) 2
GSVs for EVL/occluded (n) 67/67
Complications (n, %)
Phlebitis 2 (3)
Bruising 7 (11)
Hematoma 3 (5)
Paresthesias —
HL/S, High ligation/stripping; EVL, endovenous laser.
Fig 1. Plot of pain score during the first 10 postopera
treated with endovenous laser (EVL, solid line) ablation
in pain score between groups: P  .01.tablets.Venous Clinical Severity Score results. The mean
scores improved significantly after operation, falling from a
mean of 2.4 (range, 2 to 12) and 2.8 (range, 1 to 8) to 0.2
(range, 0 to 2) and 0.4 (range, 0 to 7) at 3 months in the
HL/S and EVL group, respectively. The scores did not
differ among the groups at any time point (Table IV). In
theHL/S group, 57 patients improved, one worsened, and
one remained unchanged. All patients improved in the
EVL group.
Aberdeen Varicose Vein Symptoms Severity Score
results. At 12 days, a clear deterioration in AVVSS was
observed in both groups. At 1 month, however, the mean
score was back to the pretreatment level, and at 3 months,
the score was significantly improved from 16.1 to 8.2 in the
HL/S group and from 18.6 to 6.9 and EVL group, with no
difference between the groups (Table IV). In the HL/S
group, 51 patients improved and eight worsened. In the
nd complications
1 month 3 months 6 months
2 5 18
66/64 63/63 50/49
— — —
2 (3) — —
— — —
1 (2) — —
— — 1 (2)
4 6 15
65/65 63/62 54/51
2 (3) — —
— — —
— — —
1 (2) — —
ays in patients with great saphenous vein insufficiency
h ligation and stripping (HL/S, dashed line). Differenceme, ative d
or higEVL group, 56 patients improved and six worsened.
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deterioration in the SF-36 domains of PF, RP, and BP. For
domains PF, RP, VT, SF, and RE, there was no significant
difference between treatment groups, but for all domains
there was a significant (P  .0001) improvement from
pretreatment to 3 months. For BP there was a significant
interaction between treatment and time (P  .042) indi-
cating that the surgery group had more bodily pain at 12
days. Furthermore, there was a significant (P  .0001)
improvement in BP from pretreatment to 3months in both
groups (Fig 2). For domains GH and MH, there was no
significant differences between the treatment groups and
no changes over time.
Costs. The comparisons of costs are shown in Table
III. Procedure-related costs were higher in the EVL group,
but the difference between the groups was somewhat re-
duced by the lower loss of productivity among the EVL
patients. The operating room time was judged to be equal
in the two groups, although it was not measured.
DISCUSSION
During the last decade new less-invasive methods have
been developed as alternatives to conventional HL/S in the
treatment of GSV incompetence, including radiofrequency
ablation (RFA), EVL, and foam sclerotherapy. The follow-
ing RCTs involving the new methods are available in the
literature:
● Four RCTs compared RFA with HL/S and showed that
RFA has significant advantages, including faster recov-
ery, less postoperative pain, fewer adverse events, and
superior quality-of-life scores.8,9,23,24
● One RCT compared EVL ablation with HL/S and
showed no difference in pain scores, but significantly less
bruising and edema occurred after EVL.25
● One RCT compared RFA with EVL and showed a
significantly increased closure rate after RFA (80% vs
Table III. Time to resume normal activity and work and
costs (€)
Variable* HL/S EVL
Time to resume normal
activity (days)
7.7  6.1 (0-29) 6.9  7.0 (0-29)
Time to resume work
(days)
7.6  4.9 (1-28) 7.0  6.0 (1-31)
Procedure-related costs
Pre-examination 191.33 191.33
Surgeons’ fees 574.93 574.93
Laser equipment — 333.33
Extra duplex imaging — 133.33
Control duplex imaging
(3 months)
157.73 157.73
Total 924 1390.66
Indirect costs
Lost work 2159.5 2005.7
Total costs (€) 3084.5 3396.4
HL/S, high ligation/stripping; EVL, endovenous laser; €, euros.
*Continuous data are presented as mean, standard deviation (range).66%), with similar complication rates.14● Two RCTs compared foam sclerotherapy with HL/S.
The first RCT showed that HL/S is superior to foam
sclerotherapy using Varisolve (BTG plc, London,United
Kingdom) for occlusion and elimination of reflux (86%
vs 63%) but that foam sclerotherapy was superior to
conventional sclerotherapy (90% vs 76%).26 The second
RCT showed that foam sclerotherapy combined with
high ligation was less expensive, involved shorter treat-
ment time, and resulted in more rapid recovery com-
pared with HL/S.27
EVL ablation of the GSV has become a frequent and
popular treatment of varicose veins due to GSV incompe-
tence in several countries. In most places, the treatment is
performed with tumescent anesthesia as an office-based
procedure, which reduces costs compared with treatment
performed in the hospital. By contrast HL/S, which so far
has been considered the gold standard treatment of vari-
cose veins, is often performed with general anesthesia in a
hospital. Under such circumstances, if the treatments pos-
sess the same safety and efficacy in both short-term and
long-term outcomes and the costs are equal, the choice
between the treatments is obvious. Most patients will select
EVL to avoid a cut in the groin and stripping, which is
considered by many to be a relatively “rough” procedure.
However, because no long-term randomized studies
comparing EVL and HL/S have been published so far,
recommendations on the choice of treatment from a med-
ical point of view must be based on theory and patient
emotions. Studies should evaluate short-term and long-
term outcomes as well as costs. To our knowledge, this
article is the first publication comparing EVL and HL/S in
a randomized trial where both treatments were performed
with tumescent anesthesia as an office-based procedure.
The study was not blinded, but we think that the risk for
bias was reduced because important variables such as pain
scores, quality-of-life scores, and indication of time off
work and normal activity were patient-reported measures
that were recorded by the research nurse and calculated by
the statistician independently of the surgeon.
In our study, EVL and HL/S were equally efficient in
eliminating the saphenous vein. Two operations (3%) failed
in the HL/S group, and in the endovenous EVL group,
three GSVs (4%) reopened between 4 weeks and 6 months
postoperatively. Our failure rates are well within the rates
published in other studies.26,27 A recent study has shown
that the risk of recanalization after EVL is reducedwhen the
energy deposition is increased and suggests a lower energy
threshold for efficacy of 38 J/cm for a vein with a diameter
of 6 mm.28 The EVL energy deposition in our study
exceeded that limit in all patients.
The frequency of adverse events was low and not dif-
ferent among the groups, apart from bruising, which was
more frequent in the HL/S group. Only oneHL/S patient
(1.5%) needed treatment for an infection in the groin. Such
infection rate is low compared with another study, where
infection occurred in 13.7% of patients after high saphe-
nous ligation.29 No DVT occurred in our study; however,
functioning; RE, role-emotional; MH, mental health.
*Data are presented as mean (range).
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Volume 46, Number 2 Rasmussen et al 313Fig 2. Medical Outcomes Study Short Form-36 bodily pain domain score during the first 6 months after treatment
with endovenous laser (EVL, solid line) ablation or high ligation and stripping (HL/S, dashed line) in patients with greatTable IV. Disease-specific and health-related quality-of-life outcomes and Venous Clinical Severity Score to 6 months
after treatment with either high ligation and stripping or endovenous laser treatment
Measure* Pretreatment 12 days 1 month 3 months 6 months
AVVSS
HL/S 16.1 (4.4-34.3) 21.5 (0-42.6) 13.7 (0-47.4) 8.2 (0-31.2) 5.3 (0-33.1)
EVL 18.6 (3.6-40.2) 23.1 (0-49.9) 14.2 (0-47.9) 6.9 (0-43.8) 7.1 (0-38.7)
VCSS
HL/S 2.4 (2-12) 0.2 (0-2) 0.2 (0-2)
EVL 2.8 (1-8) 0.1 (0-2) 0.4 (0-7)
SF-36
PF
HL/S 89.3 (25-100) 72.1 (0-100) 87.4 (18.75-100) 92.2 (43.7-100) 92.6 (50-100)
EVL 87.0 (25-100) 70.0 (6.2-100) 84.8 (25-100) 93.9 (56.2-100) 93.9 (43.7-100)
RP
HL/S 89.3 (25-100) 72.1 (0-100) 87.4 (18.7-100) 92.2 (43.7-100) 92.6 (50-100)
EVL 87.0 (25-100) 69.8 (6.2-100) 84.6 (25-100) 93.9 (56.2-100) 93.9 (43.7-100)
BP
HL/S 77.1 (22-100) 52.2 (0-100) 81.9 (41-100) 89.5 (31-100) 86.5 (20-100)
EVL 76.6 (22-100) 59.4 (22-100) 78.6 (22-100) 89.1 (32-100) 90.9 (51-100)
GH
HL/S 67.6 (28-80) 68.0 (24-80) 67.9 (20-80) 66.7 (20-80) 67.0 (33.6-80)
EVL 65.2 (32-80) 67.4 (41.6-80) 67.2 (29.6-80) 67.7 (32-80) 67.9 (40-80)
Vitality
HL/S 73.1 (12.5-100) 72.4 (37.5-100) 79.1 (25-100) 79.0 (37.5-100) 82.9 (56.2-100)
EVL 69.0 (12.5-100) 68.1 (12.5-100) 71.3 (0-100) 76.2 (18.7-100) 77.0 (18.7-100)
SF
HL/S 95.3 (62.5-100) 92.9 (62.5-100) 96.7 (50-100) 97.1 (12.5-100) 98.8 (62.5-100)
EVL 90.4 (25-100) 90.4 (0-100) 91.8 (50-100) 94.5 (37.5-100) 98.2 (62.5-100)
RE
HL/S 91.8 (50-100) 91.4 (41.7-100) 92.6 (50-100) 95.8 (58.3-100) 95.7 (50-100)
EVL 88.1 (50-100) 84.4 (16.7-100) 90.2 (41.7-100) 94.4 (33.3-100) 95.0 (58.3-100)
MH
HL/S 83.3 (35-100) 87.0 (60-100) 90.4 (65-100) 89.2 (60-100) 90.2 (70-100)
EVL 79.3 (35-100) 83.5 (45-100) 84.3 (25-100) 84.3 (25-100) 86.2 (40-100)
AVVSS Aberdeen Varicose Vein Symptoms Severity Score; HL/S, high ligation/stripping; EVL, endovenous laser; VCSS, Venous Clinical Severity Score;
SF-36, Medical Outcomes Study Short Form 36; PF, physical functioning; RP, role-physical; BP, bodily pain; GH, general health; VT, vitality; SF, socialsaphenous vein insufficiency. Difference in pain score between groups: P  .05.
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thrombus into the femoral vein. This finding is not infre-
quent after EVL of the GSV.30 It is uncertain whether the
condition should be treated, and in our patient, the throm-
bus dissolved spontaneously.
Postoperative pain in the leg was frequent in both groups.
Postoperative pain was higher after HL/S compared with
EVL, as indicated by the statistically significant differences in
pain scores and the SF-36 BP domain at 12 days. The clinical
significance of the difference in postoperative pain is uncer-
tain. Pain is a common phenomenon after HL/S and EVL
and resolves in most patients after a few weeks.25,28 Thus, at 3
months, the SF-36 BP domain was improved compared with
baseline levels. The pain after EVL does not seem to be
correlated to the laser energy deposition.28
The pain is usually located to the thigh but may also be
related to the sites of phlebectomies. The miniphlebecto-
mies may have confounded the interpretation of complica-
tions such as pain, bruising, and phlebitis. We did not count
the number of the incisions but decided to rely on the
randomization process in that respect. The multiple inci-
sions were very small, however, usually about 1.5 mm, and
did not need suture or other approximation.
The relative postoperative pain in ourHL/S groupmay
have been reduced by the tumescent anesthesia. Thus, it
has been shown that postoperative pain and the hematoma
formation after HL/S was reduced by the flush of local
anaesthetic with adrenaline through the GSV tunnel.22
However, a paired study comparing EVL (810 nm laser)
and HL/S performed with regional anesthesia found no
difference between the groups in pain, but the patients
indicated more benefit in the leg treated with laser in
addition to less bruising and edema.25 The tumescent fluid
was placed close to the GSV under ultrasound guidance in
our study, which may have further reduced the postopera-
tive pain in both groups. We did not measure pain during
the operation, but we find it likely that the intraoperative
pain was somewhat higher in the HL/S group.
The quality of life increased similarly and significantly at 3
months in both groups as indicated by the AVVSS and in all
SF-36 domains except GH and MH. At 1 month however,
the decline in the domain BP was significantly higher in the
HL/Sgroup, indicating thatHL/S is somewhatmore painful
postoperatively than EVL. Improvement in quality of life is
well-known after HL/S and EVL treatment in patients with
varicose veins, just as the transient decline shortly after the
treatment is well described.21,31 As expected, the VCSS im-
proved similarly in both groups. This finding, in addition to
the quality-of-life development, indicates that the two treat-
ments are equally efficient in eliminating GSV insufficiency
and improving venous symptoms.
The slight difference in postoperative pain did not
influence the time to resume work and normal activity,
which was approximately 1 week in both groups. The
1-week absence fromwork and normal activity found in our
HL/S group is low compared with other studies, where 2
weeks absence is more likely.8,9 The difference may be
because all of our patients were operated on with tumescentanesthesia as out-patients. In contrast, 1 week for patients
treated with EVL may be a long period, although only few
studies dealing with the issue have been published so far.
Thus, in one small study, no absence from work after EVL
treatment was reported.32 However, the time to resume
work probably depends on the type of work, which was not
recorded in the present study, and the social security sys-
tem. In Denmark, all employed individuals receive full
salary during sick leave. Such a social security system prob-
ably influences the time off work after the operation be-
cause the patients may not have been encouraged to go to
work earlier for economic reasons. Therefore, it cannot be
ruled out that the social security system in Denmark may
prolong time off from work and tend to make it similar in
the groups compared with a system where the patients
would pay themselves for sick leave.
The mean cost of the HL/S procedure was €3084
($3948 US) when loss of productivity was included com-
pared with €3396 ($4347 US) in the EVL group. It should
be emphasized, however, that the calculations are based on
the fixed procedure-related price system and the productiv-
ity level in Denmark. Thus, the cost comparisons may not
directly apply to other countries. At the 6-month follow-up
examination, 27% of HL/S and 22% of EVL patients did
not show up, perhaps because of Christmas time or perhaps
because they forgot. We have reason to believe that most of
the patients will attend the upcoming 1-year visit. We do
not think that the missing observations at 6 months weaken
the conclusions of the study to a significant degree, because
the most important observations were performed within
the first 3 postoperative months in this publication.
CONCLUSION
This study suggests that the short-term efficacy and
safety of EVL and HL/S are similar. Except for slightly
increased postoperative pain and bruising in the HL/S
group, no differences were found between the two treat-
ment modalities. The treatments were equally safe and
efficient in eliminating GSV reflux, alleviating symptoms
and signs of GSV varicosities, and improving quality of life.
Whether the relatively small cost difference should influ-
ence the choice between the treatments is, in our country,
mainly a political question, but there is no doubt that most
patients will choose EVL instead of an operation with a cut
in the groin and vein stripping. This is particularly true if the
long-term outcomes, including recurrence rates, remain
equal. Future studies, including the continuation of the
present, must address this important question.
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